Discrepancy Between Cystatin C–Based and Creatinine–Based eGFR Predicts All-Cause Mortality in a Community-Based Population: The Takahata Study

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/03c34c255ec35bf3084a8b8d388fc7fc.pdf

Abstract Title *

Discrepancy Between Cystatin C–Based and Creatinine–Based eGFR Predicts All-Cause Mortality in a Community-Based Population: The Takahata Study

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Takaya Suzuki takasuzuki124@gmail.com Yamagata University School of Medicine Department of Cardiology, Pulmonology, and Nephrology Yamagata Japan *

Co-author 2

Kazunobu Ichikawa ichikawa-k@med.id.yamagata-u.ac.jp Yamagata University School of Medicine Department of Cardiology, Pulmonology, and Nephrology Yamagata Japan -

Co-author 3

Natsuko Suzuki s-natsuko@med.id.yamagata-u.ac.jp Yamagata University School of Medicine Department of Cardiology, Pulmonology, and Nephrology Yamagata Japan -

Co-author 4

Masafumi Watanabe m-watanabe@med.id.yamagata-u.ac.jp Yamagata University School of Medicine Department of Cardiology, Pulmonology, and Nephrology Yamagata Japan -

Co-author 5

Tsuneo Konta kkonta@med.id.yamagata-u.ac.jp Yamagata University School of Medicine Department of Public Health and Hygiene Yamagata Japan -

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Discrepancies between the cystatin C–based estimated glomerular filtration rate (eGFRcys) and the creatinine–based estimated glomerular filtration rate (eGFRcr) have been linked to adverse outcomes in Western populations. However, their prognostic significance in community-dwelling Japanese individuals remains unclear. Therefore, we conducted a prospective cohort study to evaluate this association.

Methods

We analyzed data from 1,308 participants who underwent simultaneous measurements of serum creatinine and cystatin C levels between 2004 and 2006, with a median follow-up of 18.5 years. The discrepancy (eGFRdiff = eGFRcys − eGFRcr) was categorized into three groups: < −10, −10 to 10 (reference), and ≥ 10 mL/min/1.73 m². All-cause and cardiovascular mortality were assessed using Kaplan–Meier curves and Cox proportional hazards models.

Results

During the follow-up period, 386 participants (29.5%) died, including 120 cardiovascular-related deaths. Compared with the reference group, individuals in the eGFRdiff < −10 group exhibited a significantly higher risk of all-cause mortality (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.10–1.80), whereas those in the ≥ 10 group indicated a lower risk (HR: 0.56; 95% CI: 0.33–0.97). No significant association was observed with cardiovascular mortality. Incorporating eGFRdiff into the baseline models improved discrimination for both all-cause and cardiovascular mortality.

Conclusion

The discrepancy between eGFRcys and eGFRcr levels is an independent predictor of all-cause mortality in a community-based Japanese population. eGFRdiff may serve as a simple yet informative marker for identifying individuals at increased risk of death.

Kewords